Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mibavademab for monogenic obesity due to LEP gene loss-of-function variants
2024-518674-14-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of mibavademab in monogenic obesity and congenital leptin deficiency (CLD), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Percent change in Body Mass Index from baseline to week 24. Planned start Feb 2026; status: authorised.
02
Drugs
mibavademab
03
Conditions
monogenic obesitycongenital leptin deficiency (CLD)
Beyond the preview
Go deeper on 2024-518674-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518674-14-00.